These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22922304)

  • 21. Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.
    Scaruffi P; Coco S; Cifuentes F; Albino D; Nair M; Defferrari R; Mazzocco K; Tonini GP
    Cancer Genet Cytogenet; 2007 Aug; 177(1):20-9. PubMed ID: 17693187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB)].
    Pession A; De Bernardi B; Perri P; Mazzocco K; Rondelli R; Nigro M; Iolascon A; Forni M; Basso G; Conte M
    Pediatr Med Chir; 1994; 16(3):211-8. PubMed ID: 7971442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An integrated 5-Mb physical, genetic, and radiation hybrid map of a 1p36.1 region implicated in neuroblastoma pathogenesis.
    Spieker N; Beitsma M; van Sluis P; Roobeek I; den Dunnen JT; Speleman F; Caron H; Versteeg R
    Genes Chromosomes Cancer; 2000 Feb; 27(2):143-52. PubMed ID: 10612802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
    O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
    Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
    Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
    BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct cytogenetic pathways of advanced-stage neuroblastoma tumors, detected by spectral karyotyping.
    Stark B; Jeison M; Bar-Am I; Glaser-Gabay L; Mardoukh J; Luria D; Feinmesser M; Goshen Y; Stein J; Abramov A; Zaizov R; Yaniv I
    Genes Chromosomes Cancer; 2002 Jul; 34(3):313-24. PubMed ID: 12007192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
    Bown N; Cotterill S; Lastowska M; O'Neill S; Pearson AD; Plantaz D; Meddeb M; Danglot G; Brinkschmidt C; Christiansen H; Laureys G; Speleman F; Nicholson J; Bernheim A; Betts DR; Vandesompele J; Van Roy N
    N Engl J Med; 1999 Jun; 340(25):1954-61. PubMed ID: 10379019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma.
    Hiyama E; Hiyama K; Yokoyama T; Fukuba I; Yamaoka H; Shay JW; Matsuura Y
    Clin Cancer Res; 1999 Mar; 5(3):601-9. PubMed ID: 10100712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma.
    Gehring M; Berthold F; Edler L; Schwab M; Amler LC
    Cancer Res; 1995 Nov; 55(22):5366-9. PubMed ID: 7585602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
    Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
    Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.
    Uryu K; Nishimura R; Kataoka K; Sato Y; Nakazawa A; Suzuki H; Yoshida K; Seki M; Hiwatari M; Isobe T; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Koh K; Hanada R; Oka A; Hayashi Y; Ohira M; Kamijo T; Nagase H; Takimoto T; Tajiri T; Nakagawara A; Ogawa S; Takita J
    Oncotarget; 2017 Dec; 8(64):107513-107529. PubMed ID: 29296183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroblastoma: biology and staging.
    Mueller S; Matthay KK
    Curr Oncol Rep; 2009 Nov; 11(6):431-8. PubMed ID: 19840520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroblastoma: paradigm for precision medicine.
    Irwin MS; Park JR
    Pediatr Clin North Am; 2015 Feb; 62(1):225-56. PubMed ID: 25435121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TIAM1 variants improve clinical outcome in neuroblastoma.
    Sanmartín E; Yáñez Y; Fornés-Ferrer V; Zugaza JL; Cañete A; Castel V; Font de Mora J
    Oncotarget; 2017 Jul; 8(28):45286-45297. PubMed ID: 28423360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.
    Gustafson WC; Matthay KK
    Expert Rev Neurother; 2011 Oct; 11(10):1411-23. PubMed ID: 21955198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.
    Vermeulen J; De Preter K; Naranjo A; Vercruysse L; Van Roy N; Hellemans J; Swerts K; Bravo S; Scaruffi P; Tonini GP; De Bernardi B; Noguera R; Piqueras M; Cañete A; Castel V; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Michon J; Combaret V; Fischer M; Oberthuer A; Ambros PF; Beiske K; Bénard J; Marques B; Rubie H; Kohler J; Pötschger U; Ladenstein R; Hogarty MD; McGrady P; London WB; Laureys G; Speleman F; Vandesompele J
    Lancet Oncol; 2009 Jul; 10(7):663-71. PubMed ID: 19515614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics.
    Ambros IM; Brunner C; Abbasi R; Frech C; Ambros PF
    Front Oncol; 2014; 4():202. PubMed ID: 25161957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.